{"title":"Malassezia yeast population dynamics on the skin of patients living with HIV.","authors":"Abdourahim Abdillah, Isabelle Ravaux, Saadia Mokhtari, Stéphane Ranque","doi":"10.1093/mmy/myae120","DOIUrl":null,"url":null,"abstract":"<p><p>Malassezia species are lipid-dependent yeasts of the normal skin mycobiota in humans and some animals. Yet, both the dynamic of Malassezia skin colonization and the associated fungal and bacterial skin microbiome remain unknown in HIV+ patients. This study aimed to compare Malassezia yeast community structure and associated microbiome on the healthy skin of HIV+ patients and healthy controls. A total of 23 HIV+ patients and 10 healthy controls were included and followed-up for a maximum of 5 visits over 10 to 17 months. At each visit, chest, face, nasolabial fold, and scalp skin samples were subjected to both culture and MALDI-TOF MS identification, and ITS/16S metabarcoding. The participants were categorized according to their Malassezia colony forming unit (CFU) abundance. Malassezia were cultured from each participant at each visit. HIV+ patients were highly colonized on all visits with CFU >100. M. sympodialis and M. globosa were the most dominant species. M. furfur and M. dermatis were more prevalent in HIV+ than in healthy participants. M. sympodialis prevalence was stable at each sampling sites over time. M. furfur prevalence was stable and more abundant over time on HIV+ patients' chest. The metabarcoding analysis suggested a higher fungal and bacterial diversity and an increased abundance of Cladosporium halotolerans and Streptococcus in HIV+ patients than in controls. Overall, HIV+ patients display a high skin colonization by Malassezia yeasts and a dysbiosis of both fungal and bacterial communities.</p>","PeriodicalId":18586,"journal":{"name":"Medical mycology","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical mycology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/mmy/myae120","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Malassezia species are lipid-dependent yeasts of the normal skin mycobiota in humans and some animals. Yet, both the dynamic of Malassezia skin colonization and the associated fungal and bacterial skin microbiome remain unknown in HIV+ patients. This study aimed to compare Malassezia yeast community structure and associated microbiome on the healthy skin of HIV+ patients and healthy controls. A total of 23 HIV+ patients and 10 healthy controls were included and followed-up for a maximum of 5 visits over 10 to 17 months. At each visit, chest, face, nasolabial fold, and scalp skin samples were subjected to both culture and MALDI-TOF MS identification, and ITS/16S metabarcoding. The participants were categorized according to their Malassezia colony forming unit (CFU) abundance. Malassezia were cultured from each participant at each visit. HIV+ patients were highly colonized on all visits with CFU >100. M. sympodialis and M. globosa were the most dominant species. M. furfur and M. dermatis were more prevalent in HIV+ than in healthy participants. M. sympodialis prevalence was stable at each sampling sites over time. M. furfur prevalence was stable and more abundant over time on HIV+ patients' chest. The metabarcoding analysis suggested a higher fungal and bacterial diversity and an increased abundance of Cladosporium halotolerans and Streptococcus in HIV+ patients than in controls. Overall, HIV+ patients display a high skin colonization by Malassezia yeasts and a dysbiosis of both fungal and bacterial communities.
期刊介绍:
Medical Mycology is a peer-reviewed international journal that focuses on original and innovative basic and applied studies, as well as learned reviews on all aspects of medical, veterinary and environmental mycology as related to disease. The objective is to present the highest quality scientific reports from throughout the world on divergent topics. These topics include the phylogeny of fungal pathogens, epidemiology and public health mycology themes, new approaches in the diagnosis and treatment of mycoses including clinical trials and guidelines, pharmacology and antifungal susceptibilities, changes in taxonomy, description of new or unusual fungi associated with human or animal disease, immunology of fungal infections, vaccinology for prevention of fungal infections, pathogenesis and virulence, and the molecular biology of pathogenic fungi in vitro and in vivo, including genomics, transcriptomics, metabolomics, and proteomics. Case reports are no longer accepted. In addition, studies of natural products showing inhibitory activity against pathogenic fungi are not accepted without chemical characterization and identification of the compounds responsible for the inhibitory activity.